Petros Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
PTPI$0.07-46.5%Stored close · as of May 21, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | Petros Pharmaceuticals, Inc. | |
|---|---|---|
| | | |
| Date: May 13, 2026 | By: | /s/ Fady Boctor |
| | | Fady Boctor |
| | | Chief Commercial Officer and Principal Executive Officer |
| | | |
| Date: May 13, 2026 | By: | /s/ Mitchell Arnold |
| | | Mitchell Arnold |
| | | Vice President of Finance and Principal Financial Officer |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.